Advertisement

Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM

  • Xaynaly Souvannavong-Vilivong
  • Chantacha SitticharoonEmail author
  • Roongrit Klinjampa
  • Issarawan Keadkraichaiwat
  • Chanakarn Sripong
  • Saimai Chatree
  • Rungnapa Sririwichitchai
  • Tripop Lertbunnaphong
Original Article
Part of the following topical collections:
  1. Pregnancy and diabetes

Abstract

Aims

Adiponectin, visfatin, and omentin have been shown to be associated with insulin sensitivity and might have a role in the pathophysiology of gestational diabetes mellitus (GDM). This study aimed to (1) compare adiponectin, visfatin, and omentin mRNA expressions in placenta and their serum levels between normal pregnancy (NP) and GDM class A1 (GDMA1) pregnancy and (2) determine correlations between placental gene expressions as well as serum levels with maternal and neonatal clinical parameters in all, NP, and GDM subjects.

Methods

NP subjects (n = 37), who had normal medical history during their pregnancies without diagnosis of any abnormalities and GDMA1 subjects (n = 37), who were diagnosed since they had antenatal care, were recruited when they were in labor with a gestational age of at least 34 weeks. Clinical parameters and serum adiponectin, visfatin, and omentin levels were measured in the delivery room.

Results

GDMA1 subjects had higher serum visfatin and plasma glucose levels, but lower serum omentin levels (p  < 0.05 all) compared to controls, with comparable levels of placental adiponectin, visfatin, and omentin expressions, plasma insulin, and indices of insulin sensitivity and insulin resistance. Serum visfatin was negatively correlated with neonatal weight and length in the GDM group (p  < 0.05 all). Serum omentin was negatively correlated with pre-pregnancy body mass index and waist circumference only in the NP group (p  < 0.05 all). Serum adiponectin was negatively correlated with maternal age and HOMA-IR in the NP group (p  < 0.05 all) and with placental weight and serum omentin in the GDM group (p  < 0.05 all).

Conclusions

In conclusion, in GDMA1, increased serum visfatin, which has insulin-mimetic effect, might be associated with a compensatory mechanism that improves the impaired insulin function. Decreased serum omentin in GDMA1, which is normally found in visceral obesity, might lead to insulin resistance and contribute to the pathophysiology of GDM.

Keywords

GDM Insulin resistance Obesity Adiponectin Visfatin Omentin 

Notes

Acknowledgments

We thank the nurses and residents of the Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, for subject recruitment, data, blood, and placenta collection. We thank Pailin Maikaew for the management of financial documents. This work was supported by the Faculty of Medicine Siriraj Hospital Research Fund (Grant Number [IO] R015934008). X. Souvannavong-Vilivong and R. Klinjampa were supported by the Siriraj Graduate Scholarship, Faculty of Medicine Siriraj Hospital, Mahidol University. C. Sitticharoon was supported by the Chalermprakiat Grant.

Author Contributions

All authors participated in the design, interpretation of the studies and analysis of the data and review of the manuscript; XS-V, CS, RK, CS, and IK conducted the experiments. XS-V and CS wrote the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no potential conflicts of interest.

Ethical approval

The study has been approved by the the Siriraj Institutional Review Board (COA no. Si.545/2015) of the Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand and has been performed in accordance with the Declaration of Helsinki.

Informed consent

Written informed consents were obtained from all subjects prior to the study.

References

  1. 1.
    Kane SC, Costa Fda S, Brennecke S (2014) First trimester biomarkers in the prediction of later pregnancy complications. Biomed Res Int 2014:807196CrossRefGoogle Scholar
  2. 2.
    De Souza LR, Berger H, Retnakaran R et al (2016) First-trimester maternal abdominal adiposity predicts dysglycemia and gestational diabetes mellitus in midpregnancy. Diabetes Care 39(1):61–64CrossRefGoogle Scholar
  3. 3.
    Bluher M (2012) Clinical relevance of adipokines. Diabetes Metab J. 36(5):317–327CrossRefGoogle Scholar
  4. 4.
    Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270(45):26746–26749CrossRefGoogle Scholar
  5. 5.
    Chen J, Tan B, Karteris E et al (2006) Secretion of adiponectin by human placenta: differential modulation of adiponectin and its receptors by cytokines. Diabetologia 49(6):1292–1302CrossRefGoogle Scholar
  6. 6.
    Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7(8):941–946CrossRefGoogle Scholar
  7. 7.
    Sitticharoon C, Nway NC, Chatree S, Churintaraphan M, Boonpuan P, Maikaew P (2014) Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors. Peptides 62:164–175CrossRefGoogle Scholar
  8. 8.
    Derosa G, Fogari E, D’Angelo A et al (2013) Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 36(4):914–920.  https://doi.org/10.1007/s10753-013-9620-4 CrossRefGoogle Scholar
  9. 9.
    Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5):1930–1935CrossRefGoogle Scholar
  10. 10.
    Park KG, Park KS, Kim MJ et al (2004) Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract 63(2):135–142CrossRefGoogle Scholar
  11. 11.
    Catalano PM, Hoegh M, Minium J et al (2006) Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia 49(7):1677–1685 Epub 2006 May 11 CrossRefGoogle Scholar
  12. 12.
    Lowe LP, Metzger BE, Lowe WL Jr, Dyer AR, McDade TW, McIntyre HD (2010) Inflammatory mediators and glucose in pregnancy: results from a subset of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. J Clin Endocrinol Metab 95(12):5427–5434CrossRefGoogle Scholar
  13. 13.
    Matuszek B, Burska A, Leszczynska-Gorzelak B, Donica H, Nowakowski A (2013) Comparative analysis of adiponectin isoform distribution in pregnant women with gestational diabetes mellitus and after delivery. Acta Obstet Gynecol Scand 92(8):951–959CrossRefGoogle Scholar
  14. 14.
    Xu J, Zhao YH, Chen YP et al (2014) Maternal circulating concentrations of tumor necrosis factor-alpha, leptin, and adiponectin in gestational diabetes mellitus: a systematic review and meta-analysis. Sci World J 2014:926932Google Scholar
  15. 15.
    Pala HG, Ozalp Y, Yener AS, Gerceklioglu G, Uysal S, Onvural A (2015) Adiponectin levels in gestational diabetes mellitus and in pregnant women without glucose intolerance. Adv Clin Exp Med. 24(1):85–92.  https://doi.org/10.17219/acem/38141 CrossRefGoogle Scholar
  16. 16.
    Adeghate E (2008) Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 15(18):1851–1862CrossRefGoogle Scholar
  17. 17.
    Morgan SA, Bringolf JB, Seidel ER (2008) Visfatin expression is elevated in normal human pregnancy. Peptides 29(8):1382–1389.  https://doi.org/10.1016/j.peptides.2008.04.010 Epub Apr 26 CrossRefGoogle Scholar
  18. 18.
    Chan TF, Chen YL, Lee CH et al (2006) Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 13(5):364–367CrossRefGoogle Scholar
  19. 19.
    Fukuhara A, Matsuda M, Nishizawa M et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430 Epub 2004 Dec 16 CrossRefGoogle Scholar
  20. 20.
    Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M et al (2006) Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55(10):2871–2875CrossRefGoogle Scholar
  21. 21.
    Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH (2011) Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin Chem 57(4):609–613.  https://doi.org/10.1373/clinchem.2010.159806 Epub 2011 Feb 15 CrossRefGoogle Scholar
  22. 22.
    Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J et al (2007) Serum concentration of visfatin in obese women. Metabolism. 56(8):1131–1134CrossRefGoogle Scholar
  23. 23.
    Sitticharoon C, Nway NC, Chatree S, Churintaraphan M, Boonpuan P, Maikaew P (2014) Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors. Peptides 62:164–175CrossRefGoogle Scholar
  24. 24.
    Derosa G, Fogari E, D’Angelo A et al (2013) Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 36:914–920CrossRefGoogle Scholar
  25. 25.
    Pagano C, Pilon C, Olivieri M et al (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91(8):3165–3170CrossRefGoogle Scholar
  26. 26.
    Krzyzanowska K, Krugluger W, Mittermayer F et al (2006) Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond). 110(5):605–609CrossRefGoogle Scholar
  27. 27.
    Telejko B, Kuzmicki M, Zonenberg A et al (2009) Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. Diabetes Res Clin Pract 84(1):68–75.  https://doi.org/10.1016/j.diabres.2008.12.017 Epub 9 Jan 30 CrossRefGoogle Scholar
  28. 28.
    Tan BK, Adya R, Randeva HS (2010) Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 20(5):143–148.  https://doi.org/10.1016/j.tcm.2010.12.002 CrossRefGoogle Scholar
  29. 29.
    Tsuji S, Uehori J, Matsumoto M et al (2001) Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 276(26):23456–23463CrossRefGoogle Scholar
  30. 30.
    Maenhaut N, Van de Voorde J (2011) Regulation of vascular tone by adipocytes. BMC Med 9:25CrossRefGoogle Scholar
  31. 31.
    Tan BK, Adya R, Farhatullah S et al (2008) Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 57(4):801–808CrossRefGoogle Scholar
  32. 32.
    de Souza Batista CM, Yang RZ, Lee MJ et al (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56(6):1655–1661 Epub 2007 Feb 28 CrossRefGoogle Scholar
  33. 33.
    Barker G, Lim R, Georgiou HM, Lappas M (2012) Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity. PLoS ONE 7(8):e42943CrossRefGoogle Scholar
  34. 34.
    Lewandowski K, Nadel I, Lewinski A et al (2010) Positive correlation between serum omentin and thrombospondin-1 in gestational diabetes despite lack of correlation with insulin resistance indices. Ginekol Pol 81(12):907–912Google Scholar
  35. 35.
    Lappas M, Yee K, Permezel M, Rice GE (2005) Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol 186(3):457–465CrossRefGoogle Scholar
  36. 36.
    White P (1949) Pregnancy complicating diabetes. Am J Med 7(5):609–616CrossRefGoogle Scholar
  37. 37.
    Abell SK, De Courten B, Boyle JA, Teede HJ (2015) Inflammatory and other biomarkers: role in pathophysiology and prediction of gestational diabetes mellitus. Int J Mol Sci 16(6):13442–13473CrossRefGoogle Scholar
  38. 38.
    Sunsaneevithayakul P, Boriboohirunsarn D, Sutanthavibul A et al (2003) Risk factor-based selective screening program for gestational diabetes mellitus in Siriraj Hospital: result from clinical practice guideline. J Med Assoc Thail 86(8):708–714Google Scholar
  39. 39.
    Cleal JK, Day P, Hanson MA, Lewis RM (2009) Measurement of housekeeping genes in human placenta. Placenta 30(11):1002–1003CrossRefGoogle Scholar
  40. 40.
    Coskun A, Ozkaya M, Kiran G, Kilinc M, Arikan DC (2010) Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus. J Matern Fetal Neonatal Med. 23(9):1014–1018CrossRefGoogle Scholar
  41. 41.
    Gabbe SG (1981) Diabetes mellitus in pregnancy: have all the problems been solved? Am J Med 70(3):613–618CrossRefGoogle Scholar
  42. 42.
    Shokry E, Marchioro L, Uhl O et al (2019) Impact of maternal BMI and gestational diabetes mellitus on maternal and cord blood metabolome: results from the PREOBE cohort study. Acta Diabetol 56(4):421–430CrossRefGoogle Scholar
  43. 43.
    Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49(8):1909–1914CrossRefGoogle Scholar
  44. 44.
    Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91(4):1578–1581CrossRefGoogle Scholar
  45. 45.
    Szamatowicz J, Kuzmicki M, Telejko B et al (2009) Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes. Ginekol Pol 80(1):14–18Google Scholar
  46. 46.
    Akturk M, Altinova AE, Mert I et al (2008) Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J Endocrinol Invest 31(7):610–613CrossRefGoogle Scholar
  47. 47.
    Nway NC, Sitticharoon C, Chatree S, Maikaew P (2016) Correlations between the expression of the insulin sensitizing hormones, adiponectin, visfatin, and omentin, and the appetite regulatory hormone, neuropeptide Y and its receptors in subcutaneous and visceral adipose tissues. Obes Res Clin Pract. 10(3):256–263CrossRefGoogle Scholar
  48. 48.
    Bergmann K, Sypniewska G (2013) Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? Clin Chem Lab Med. 51(1):177–185CrossRefGoogle Scholar
  49. 49.
    Kabir M, Catalano KJ, Ananthnarayan S et al (2005) Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 288(2):E454–E461CrossRefGoogle Scholar
  50. 50.
    Simons PJ, van den Pangaart PS, Aerts JM, Boon L (2007) Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol 192(2):289–299CrossRefGoogle Scholar
  51. 51.
    Mohlig M, Wegewitz U, Osterhoff M et al (2002) Insulin decreases human adiponectin plasma levels. Horm Metab Res 34(11–12):655–658CrossRefGoogle Scholar
  52. 52.
    Hivert M-F, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB (2011) Higher adiponectin levels predict greater weight gain in healthy women in the Nurses’ Health Study. Obesity (Silver Spring, Md). 19(2):409–415CrossRefGoogle Scholar
  53. 53.
    Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132(6):2169–2180CrossRefGoogle Scholar
  54. 54.
    Simons PJ, van den Pangaart PS, Aerts JM, Boon L (2007) Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol 192(2):289–299CrossRefGoogle Scholar
  55. 55.
    Zheng J, Xiao X, Zhang Q et al (2014) Correlation of high-molecular-weight adiponectin and leptin concentrations with anthropometric parameters and insulin sensitivity in newborns. Int J Endocrinol 2014:435376Google Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

Authors and Affiliations

  • Xaynaly Souvannavong-Vilivong
    • 1
  • Chantacha Sitticharoon
    • 1
    Email author
  • Roongrit Klinjampa
    • 1
    • 2
  • Issarawan Keadkraichaiwat
    • 1
  • Chanakarn Sripong
    • 1
  • Saimai Chatree
    • 1
  • Rungnapa Sririwichitchai
    • 1
  • Tripop Lertbunnaphong
    • 3
  1. 1.Department of Physiology, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand
  2. 2.Faculty of Medicine and Public Health, HRH Princess Chulabhorn College of Medical ScienceChulabhorn Royal AcademyBangkokThailand
  3. 3.Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand

Personalised recommendations